IHMT-PI3Kδ-372

• UNSPSC Description:

  IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research[1].

• Target Antigen:

  Cytochrome P450; PI3K

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease;PI3K/Akt/mTOR

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ihmt-pi3kδ-372.html

• Solubility:

  DMSO : 41.67 mg/mL (ultrasonic)

• Smiles:

  O=C1N(C2CC2)C([C@@H](N3N=C(C4=CC=C(OC)C(F)=C4)C5=C(N)N=CN=C53)CC)=NC6=C1C(F)=CC=C6

• Molecular Weight:

  503.50

• References & Citations:

  [1]Feng Li, et al. Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1 H-pyrazolo[3,4- d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3 H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. J Med Chem. 2020 Nov 25;63(22):13973-13993.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2429889-61-0